拉米夫定联合胸腺五肽治疗慢性乙型肝炎疗效观察

目的：探索抗病毒药物联合免疫调节药物治疗慢性乙型肝炎的疗效。方法：采用拉米夫定联合胸腺五肽治疗慢性乙型肝炎，同期单用拉米夫定或胸腺五肽作对照，动态观察血清HBV复制指标及肝功能。结果：治疗结束时联合组血清HBeAg阴转及抗HBe阳转率明显优于拉米夫定组（P＜0．05），与胸腺五肽组比较差异无显著性（P＞0．05）；联合组的HBV DNA阴转率优于胸腺五肽组（P＜0．05），与拉米夫定组比较差异无显著性（P＞0．05）。治疗结束后6个月、12个月的病毒复制指标变化与治疗结束时无明显变化。联合组的显效率及总有效率均高于其他两组，且ALT复常率保持在85％以上。结论：拉米夫定联合胸腺五肽治疗慢性乙型肝炎，可达到有效而持续的抗病毒作用。亦有利于ALT持久复常。

Therapeutic effects of Lamivudine in combination with Thymopentin on chronic hepatitis B

Objective To explore the efficacy of anti viral drug in combination with immunoregulatory agent in treatment of chronic hepatitis B.Methods Totally 98 patients with chronic hepatitis B were divided at random into 3 groups. In groups A (42 cases) lamivudine was used in combination with thymopentin to treat chronic hepatitis B.Lamivudine or thymopentin was used alone in groups B (38 cases) and C (18 cases),respectively.The dynamic changes in serum parameters reflecting HBV replication and liver function were observed. Results At the end of the treatments,the rates of negative conversion of HBeAg and positive conversion of anti HBe in the serum were significantly higher in group A than in group B ( P <0.05).There was no significant difference between group A and group C ( P >0.05).The rate of negative conversion of HBV DNA was markedly higher in group A than in group C ( P <0.05).However,there was no remarkable difference between group A and group B ( P >0.05).The changes in parameters of viral replication in 6 and 12 months after the treatments were not significantly different from those at the end of the treatments.The effective rate and total effective rate were markedly higher in group A than in the other 2 groups.Meanwhile,the rate of ALT normalizaion of remained higher than 85% in group A.Conclusion Lamivudine in combination with thymopentin can exert great and lasting effects on HBV and is effective in normalization of ALT.